natgillin/translations-raw huggingface dataset:
Inovelon tages to gange dagligt sammen med vand og mad.
Inovelon should be taken with water and food twice a day.
INR ≤ 1,3 for vitamin K- antagonister, eller andre relevante test for øvrige orale antikoagulantia er indenfor de respektive øvre normalgrænser).
INR ≤ 1.3 for vitamin K antagonists or other relevant test(s) for other oral anticoagulants are within the respective upper limit of normal).
INR-
Astemizole
INR-måling som mål for VKAs effekt kan først anvendes mindst 2 dage efter, Pradaxa er blevet seponeret, idet Pradaxa kan øge INR.
Because Pradaxa can increase INR, the INR will better reflect VKA’s effect only after Pradaxa has been stopped for at least 2 days.
INR-test bør ikke anvendes, da det ikke er et pålideligt mål for Xareltos antikoagulerende aktivitet.
INR values should not be used as they are not a dependable measure of the anticoagulant activity of Xarelto.
INR-værdien er upålidelig hos patienter i behandling med Pradaxa, og der er rapporteret falsk positive INR-stigninger.
The INR test is unreliable in patients on Pradaxa and false positive INR elevations have been reported.
INR-værdier i henhold til AF-retningslinjer ved behandling med vitamin K antagonist.
INR values in case of vitamin K antagonist therapy as per clinical AF guidelines.
INR-værdierne øgedes i gennemsnit med 13% (CI90 6-19%).
The INR values increased on average by 13% [CI90 6-19%].
INR-værdierne øgedes i gennemsnit med 13% [CI90 6-19%].
The INR values increased on average by 13% [CI90 6–19%].
Insekterne behøver ikke indtage dinotefuran.
Insects do not have to ingest dinotefuran.
insomni
insomnia
insomni
with sulpho- nylurea
Insomni Pruritus
Insomnia Pruritus
Insomni*
Insomnia
insomni, abnorme drømme
insomnia, abnormal dreams
Insomni, angst
Insomnia, anxiety
Insomni, angst, depression
insomnia, anxiety, depression
insomni, angst, forvirring
insomnia, anxiety, confusion
Insomni, apati, depression, nervøsitet, agitation, irritabilitet, nedsat opmærksomhed/hyper- aktivitet, konfusion, stemningslabilitet, grådlabilitet, psykomotorisk retardering, stress, psykose
Insomnia, apathy, depression, nervousness, agitation, irritability, attention deficit/ hyperactivity disorder, confusional state, mood swings, crying, psychomotor retardation, stress, psychotic disorder
Insomni, humørsvingninger (inklusive angst), depression, tremor, smagsforstyrrelser, synkope, hypæstesi, synsforstyrrelser (herunder diplopi), tinnitus, hypotension, dyspnø, rhinitis, opkastning, dyspepsi, alopeci, purpura, misfarvning af huden, hyperhidrose, pruritus, eksantem, myalgi, muskelkramper, smerter, vandladningsforstyrrelser, øget vandladningshyppighed, impotens, gynækomasti, brystsmerter, utilpashed, vægtstigning, vægttab.
Insomnia, mood changes (including anxiety), depression, tremor, dysgeusia, syncope, hypoesthesia, visual disturbance (including diplopia), tinnitus, hypotension, dyspnoea, rhinitis, vomiting, dyspepsia, alopecia, purpura, skin discolouration, hyperhidrosis, pruritus, exanthema, myalgia, muscle cramps, pain, micturition disorder, increased urinary frequency, impotence, gynaecomastia, chest pain, malaise, weight increase, weight decrease.
insomni, irritabilitet
insomnia, irritability
Insomni, mareridt, amnesi
Insomnia, nightmares, memory loss.
Insomni/søvnforstyrrelser
Insomnia/sleep disturbances
insomni1, 2
insomnia1, 2
Insomnia, hypæstesi, paræstesi Oral paræstesi
insomnia, hypoaesthesia; paraesthesia oral paraesthesia.
Inspektionsvindue Grøn mærkat
Inspection window Green label
Inspektionsvinduet i pennen skal nu være helt lilla som tegn på at injektionen er udført korrekt (se billede 8).
The pen’s inspection window should now be completely purple, confirming that the dose has been injected correctly (see Diagram 8).
Inspicer alle nye cylinderampuller før brugen.
Inspect all new cartridges prior to use.
Inspicer for synlige partikler og misfarvning før administration.
Inspect visually for particulate matter and discoloration prior to administration.
Inspicer hætteglasset med ZALTRAP visuelt før brug.
Inspect the ZALTRAP vial visually prior to use.
Inspicer indholdet af hætteglasset før brug.
Before using, the vial contents should be inspected.
Inspicer indholdet i hætteglasset.
Inspect the vial content.
Inspicer opløsningen for partikler og misfarvning før yderligere fortynding.
Inspect the resulting solution for particulate matter and discoloration prior to further dilution.
Inspicer opløsningen for partikler og misfarvning.
Inspect the infusion solution for particulate matter or discoloration.
Inspicer opløsningen, og hvis den indeholder partikler, eller hvis den ikke er farveløs til svagt gullig i farve, må indholdet ikke anvendes.
Inspect the reconstituted product: If it contains particulate matter or is other than colourless to slightly yellow in colour, the vial must not be used.
Inspicer pennen for at sikre, at nummeret ‘1’ er synligt i nummervinduet.
Inspect the pen to ensure that the number ‘1’ is visible in the number window.
Inspicer straks de rekonstituerede hætteglas for partikler og misfarvning.
Perform an immediate inspection of the reconstituted vials for particulate matter and discoloration.
Inspicer visuelt den rekonstituerede OBIZUR opløsning for partikelmateriale og misfarvning inden administration.
Inspect the reconstituted OBIZUR solution for particulate matter and discoloration prior to administration.
Inspicer visuelt for partikler og misfarvning før anvendelse.
Inspect visually for particulate matter and discoloration prior to administration.
Inspicér suspensionen visuelt for partikler og misfarvning før administration.
Inspect the suspension visually for particulate matter and discolouration prior to administration.
Inspicér visuelt den opløste infusionsvæske.
Inspect visually the reconstituted solution.
Inspicér visuelt den rekonstituerede infusionsvæske.
Inspect visually the reconstituted solution.
Inspireret koncentration
Inspired concentration:
Inspireret koncentration:
Inspired Concentration:
Instant tyndtlagskromatografi eller papirkromatografi
Instant thin layer chromatography or paper chromatography.
Instanyl 100 mikrog næsespray Fentanyl
Instanyl 100 mcg nasal spray Fentanyl
Instanyl 100 mikrogram næsespray Fentanyl
Instanyl 100 micrograms nasal spray Fentanyl
Instanyl 100 mikrogram næsespray, opløsning, enkeltdosisbeholder Fentanyl
Instanyl 100 micrograms nasal spray, solution in single-dose container Fentanyl
Instanyl 100 mikrogram, næsespray, opløsning, enkeltdosisbeholder
Instanyl 100 micrograms nasal spray, solution in single-dose container
Instanyl 100 mikrogram, næsespray, opløsning, enkeltdosisbeholder 36 måneder
Instanyl 100 micrograms nasal spray, solution in single-dose container 36 months
Instanyl 100 mikrogram/dosis næsespray, opløsning Fentanyl
Instanyl 100 micrograms/dose nasal spray Fentanyl
Instanyl 100 mikrogram/dosis næsespray, opløsning Fentanyl
Instanyl 100 micrograms/dose nasal spray, solution Fentanyl
Instanyl 100 mikrogram/dosis, næsespray, opløsning
Instanyl 100 micrograms/dose nasal spray, solution
Instanyl 100, endosis
Instanyl 100, single-dose
Instanyl 200 mikrog næsespray Fentanyl
Instanyl 200 mcg nasal spray Fentanyl
Instanyl 200 mikrogram næsespray Fentanyl
Instanyl 200 micrograms nasal spray Fentanyl
Instanyl 200 mikrogram næsespray, opløsning, enkeltdosisbeholder Fentanyl
Instanyl 200 micrograms nasal spray, solution in single-dose container Fentanyl
Instanyl 200 mikrogram, næsespray, opløsning, enkeltdosisbeholder
Instanyl 200 micrograms nasal spray, solution in single-dose container
Instanyl 200 mikrogram/dosis næsespray, opløsning Fentanyl
Instanyl 200 micrograms/dose nasal spray Fentanyl
Instanyl 200 mikrogram/dosis næsespray, opløsning Fentanyl
Instanyl 200 micrograms/dose nasal spray, solution Fentanyl
Instanyl 200 mikrogram/dosis, næsespray, opløsning
Instanyl 200 micrograms/dose nasal spray, solution
Instanyl 200, endosis
Instanyl 200, single-dose
Instanyl 50 mikrog næsespray Fentanyl
Instanyl 50 mcg nasal spray Fentanyl
Instanyl 50 mikrogram næsespray Fentanyl
Instanyl 50 micrograms nasal spray Fentanyl
Instanyl 50 mikrogram næsespray, opløsning, enkeltdosisbeholder Fentanyl
Instanyl 50 micrograms nasal spray, solution in single-dose container Fentanyl
Instanyl 50 mikrogram næsespray, opløsning, enkeltdosisbeholder Instanyl 100 mikrogram næsespray, opløsning, enkeltdosisbeholder Instanyl 200 mikrogram næsespray, opløsning, enkeltdosisbeholder Fentantyl
Instanyl 50 micrograms nasal spray, solution in single-dose container Instanyl 100 micrograms nasal spray, solution in single-dose container Instanyl 200 micrograms nasal spray, solution in single-dose container Fentanyl
Instanyl 50 mikrogram, næsespray, opløsning, enkeltdosisbeholder
Instanyl 50 micrograms nasal spray, solution in single-dose container
Instanyl 50 mikrogram, næsespray, opløsning, enkeltdosisbeholder Instanyl 100 mikrogram, næsespray, opløsning, enkeltdosisbeholder Instanyl 200 mikrogram, næsespray, opløsning, enkeltdosisbeholder
Instanyl 50 micrograms nasal spray, solution in single-dose container Instanyl 100 micrograms nasal spray, solution in single-dose container Instanyl 200 micrograms nasal spray, solution in single-dose container
Instanyl 50 mikrogram/dosis næsespray, opløsning Fentanyl
Instanyl 50 micrograms/dose nasal spray Fentanyl
Instanyl 50 mikrogram/dosis næsespray, opløsning Fentanyl
Instanyl 50 micrograms/dose nasal spray, solution Fentanyl
Instanyl 50 mikrogram/dosis næsespray, opløsning Instanyl 100 mikrogram/dosis næsespray, opløsning Instanyl 200 mikrogram/dosis næsespray, opløsning Fentantyl
Instanyl 50 micrograms/dose nasal spray, solution Instanyl 100 micrograms/dose nasal spray, solution Instanyl 200 micrograms/dose nasal spray, solution Fentanyl
Instanyl 50 mikrogram/dosis, næsespray, opløsning
Instanyl 50 micrograms/dose nasal spray, solution
Instanyl 50, endosis
Instanyl 50, single-dose
Instanyl anvendes til at behandle "gennembrudssmerter" hos voksne kræftpatienter. ”Gennembrudssmerte” er, når en patient oplever yderligere, pludselig smerte på trods af igangværende behandling med smertestillende midler.
Instanyl is used to treat ‘breakthrough’ pain in adults with cancer. ‘Breakthrough pain’ is when a patient experiences additional, sudden pain in spite of ongoing treatment with painkillers.
Instanyl anvendes til patienter, som i forvejen anvender opioider (en gruppe smertestillende midler, som omfatter morfin og fentanyl) til at kontrollere længerevarende kræftsmerter.
Instanyl is used in patients who are already using opioids (a group of painkillers that includes morphine and fentanyl) to control long-term cancer pain.
Instanyl bør kun anvendes på tvingende indikation til gravide.
Instanyl should not be used in pregnancy unless clearly necessary.
Instanyl DoseGuard er en næsespray, opløsning.
Instanyl DoseGuard is a nasal spray, solution.
Instanyl er en næsespray, der indeholder det aktive stof fentanyl (50, 100 og 200 mikrogram pr. dosis).
Instanyl is a nasal spray that contains the active substance fentanyl (50, 100 and 200 micrograms per dose).
Instanyl er en næsespray, opløsning.
Instanyl is a nasal spray, solution.
Instanyl er en opløsning i en enkeltdosisspraybeholder.
Instanyl is a nasal spray, solution in a single-dose spray container.
Instanyl er indiceret til behandling af gennembrudssmerter hos voksne, der i forvejen er i vedligeholdelsesbehandling med opioider for kroniske cancersmerter.
Instanyl nasal spray is only indicated for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain.
Instanyl kan medføre svimmelhed og døsighed, som kan påvirke din evne til at føre motorkøretøjer eller betjene maskiner.
Instanyl can cause dizziness and drowsiness, which may affect your ability to drive or use machines.
Instanyl kan påvirke disse lægemidler, og du kan opleve ændringer af din mentale status (f.eks. ophidselse, hallucinationer, koma) og andre virkninger som en kropstemperatur over 38 °C, øget hjertefrekvens, ustabilt blodtryk og overdrevne reflekser, muskelstivhed, manglende koordination og/eller mave-tarm-symptomer (f.eks. kvalme, opkastning, diarré).
Instanyl may interact with these medicines and you may experience mental status changes (e.g. agitation, hallucinations, coma), and other effects such as body temperature above 38°C, increase in heart rate, unstable blood pressure, and exaggeration of reflexes, muscular rigidity, lack of coordination and/or gastrointestinal symptoms (e.g nausea, vomiting, diarrhoea).
Instanyl må ikke anvendes til børn og unge under 18 år.
Instanyl should not be used in children and adolescents under 18 years of age.
Instanyl må ikke anvendes til patienter, som ikke i forvejen tager opioider til at hold smerterne under kontrol, eller til patienter, som har svær respirationsdepression (åndedrætsbesvær) eller svære obstruktive lungesygdomme (sygdomme, der giver alvorlige vejrtrækningsproblemer).
Instanyl must not be used in patients who are not already taking opioids to maintain pain control, who have severe respiratory depression (inhibition of breathing) or who have severe obstructive lung conditions (diseases that severely impede breathing).
Instanyl næsespray bør ikke anvendes til at behandle andre former for kortvarige smerter og smertetilstande.
Instanyl nasal spray should not be used to treat any other short-term pain or pain status.
Instanyl næsespray bør kun ordineres af læger, som har erfaring med, er velinformeret og kvalificeret ibehandling af cancerpatienter med opioider.
Instanyl nasal spray should be used only by physicians experienced, knowledgeable and skilled in the management of opioid therapy in cancer patients.
Instanyl næsespray er kun indiceret og godkendt til behandling af gennembrudssmerter hos voksne, som allerede modtager vedligeholdelses-opioidbehandling for kroniske cancersmerter.
Instanyl nasal spray is only indicated and licensed for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain.
Instanyl skal opbevares utilgængeligt for børn.
Instanyl must be kept out of reach and sight of children.
Instanyl var mere effektivt end placebo til behandling af gennembrudssmerter hos kræftpatienter.
Instanyl was more effective than placebo at treating breakthrough pain in cancer patients.
Instanyl virker meget hurtigt og bruges til lindring af gennembrudssmerter hos voksne cancerpatienter, som allerede er i behandling med opioider for deres baggrundssmerter.
Instanyl acts very fast and is used for relieving breakthrough pain in adult cancer patients already treated with opioids for their usual pain.
Instanyls sikkerhed og virkning hos børn under 18 år er endnu ikke klarlagt.
The safety and efficacy of Instanyl in children aged below 18 years have not yet been established.
Institutionens regningslinjer for håndtering og administration, personligt beskyttelsesudstyr, uforsætlige spild og bortskaffelse af affald skal følges.
Follow local institutional guidelines for handling and administration, personal protective equipment, accidental spills, and waste disposal.
Instituto Grifols, S.A. Polígono Levante Can Guasc, 2
Instituto Grifols, S.A. Polígono Levante Can Guasc, 2,
INSTRUCCIONES DE USO
INSTRUCTIONS ON USE
INSTRUCTIES VOOR GEBRUIK
INSTRUCTIONS ON USE
Instruer dyrets ejer i at at holde injektionsstedet rent og tørt i 24 timer.
Instruct the owner to keep the administration site clean and dry for 24 hours.
Instruer dyrets ejer om at holde administrationsstedet rent og tørt i 24 timer.
Instruct the owner to keep the administration site clean and dry for 24 hours.
Instruer dyrets ejer om at holde injektionsstedet rent og tørt i 24 timer.
Instruct the owner to keep the administration site clean and dry for 24 hours.
Instruksioner vedrørende infusionshastigheden er vist i tabel 5 og 6.
Instructions on the rate of infusion are shown in Tables 5 and 6.
Instruktion
Instructions for use
Instruktion for administration af vaccine i fyldt injektionssprøjte
Instructions for administration of the vaccine presented in pre-filled syringe
Instruktion for administration af vaccine i fyldt injektionssprøjte:
Instructions for administration of the vaccine presented in pre-filled syringe
Instruktion for administration af vaccinen:
Instructions for administration of the vaccine
Instruktion for tilberedning af reducerede doser af Zoledronsyre Accord: Udtag det passende volumen af det flydende koncentrat som følger:
Instructions for preparing reduced doses of Zoledronic Acid Accord: Withdraw the appropriate volume of the liquid concentrate, as follows:
Instruktion for tilberedning af reducerede doser af Zoledronsyre Actavis: Udtag det passende volumen af det flydende koncentrat efter følgende:
Instructions for preparing reduced doses of Zoledronic acid Actavis: Withdraw the appropriate volume of the liquid concentrate, as follows:
Instruktion for tilberedning af reducerede doser af Zoledronsyre Hospira: Udtag det passende volumen af det flydende koncentrat efter følgende:
Instructions for preparing reduced doses of Zoledronic Acid Hospira: Withdraw the appropriate volume of the liquid concentrate, as follows:
Instruktion for tilberedning af reducerede doser af Zoledronsyre Mylan: Udtag det passende volumen af det flydende koncentrat efter følgende:
Instructions for preparing reduced doses of Zoledronic acid Mylan: Withdraw the appropriate volume of the liquid concentrate, as follows:
Instruktion for tilberedning af reducerede doser af Zoledronsyre Teva: Udtag det passende volumen af det flydende koncentrat efter følgende:
Instructions for preparing reduced doses of Zoledronic Acid Teva: Withdraw the appropriate volume of the liquid concentrate, as follows:
Instruktion i administration
Instructions for administration
Instruktion i anvendelse og håndtering - rekonstitution, fortynding og administration
Instructions for use and handling – reconstitution, dilution and administration
Instruktion i anvendelse og håndtering – opbevaring
Instructions for use and handling - storage conditions
Instruktion i anvendelse og håndtering – opbevaring
Instructions for use and handling – storage conditions
Instruktion i at anvende OptiClik, insulinpennen, er vedlagt din OptiClik insulinpen.
The instructions for using OptiClik, the insulin pen, are provided with your OptiClik.
Instruktion i fortynding, opbevaring og bortskaffelse af Topotecan Teva Generelle forholdsregler
Instructions on how to dilute, store and dispose of Topotecan Teva General precautions
Instruktion i fremstilling af reducerede doser af Zoledronsyre medac Udtag en passende volumen af koncentratet på følgende måde:
Instructions for preparing reduced doses of Zoledronic acid medac Withdraw an appropriate volume of the concentrate needed, as follows:
Instruktion i fremstilling af reducerede doser Zoledronsyre Actavis Udtag en passende volumen af koncentratet efter følgende:
Instructions for preparing reduced doses of Zoledronic acid Actavis Withdraw an appropriate volume of the concentrate needed, as follows:
Instruktion i fremstilling af reducerede doser Zoledronsyre Teva Udtag en passende volumen af koncentratet efter følgende:
Instructions for preparing reduced doses of Zoledronic Acid Teva Withdraw an appropriate volume of the concentrate needed, as follows:
Instruktion i korrekt klargøring af vaccinen til indgivelse
The correct way to prepare the vaccine prior to administration.
Instruktion i korrekt tilberedning af vaccinen forud for administration.
The correct way to prepare the vaccine prior to administration.
Instruktion i omgående at ophøre med pomalidomid, hvis der er mistanke om graviditet
Instructions to stop pomalidomide immediately upon suspicion of pregnancy
Instruktion i omgående at ophøre med Revlimid, hvis der er mistanke om graviditet
Instructions to stop Revlimid immediately upon suspicion of pregnancy
Instruktion i rekonstituering af vaccinen med solvens i ampul
Instructions for reconstitution of the vaccine with the solvent presented in ampoules:
Instruktion i rekonstitution, opbevaring og bortskaffelse af Hycamtin Rekonstitution
Instructions on how to reconstitute, store and dispose of Hycamtin Reconstitution
Instruktion i åbning af de børnesikrede blisterkort: Tryk tabletten ud af blisterkortet.
Instructions for opening the child-resistant blisters: Push the tablet for release from the blister.
Instruktion i, hvordan du giver dig selv en indsprøjtning (kun til patienter med symptomatisk anæmi forårsaget af nyresygdom til patienter, der får kemoterapi, og voksne patienter, som skal gennemgå ortopædkirurgi)
Instructions on how to inject yourself (for patients with symptomatic anaemia caused by kidney disease, for patients receiving chemotherapy or adult patients scheduled for orthopaedic surgery only)
Instruktion i, hvordan du giver dig selv en indsprøjtning (kun til patienter, der får kemoterapi, og voksne patienter, som skal gennemgå ortopædkirurgi)
Instructions on how to inject yourself (for patients receiving chemotherapy or adult patients scheduled for orthopaedic surgery only)
Instruktion i, hvordan man tager Pradaxa
An instruction how to take Pradaxa
Instruktion om indberetning af bivirkninger, såfremt der findes et særligt indberetningssystem.
If a specific notification system has been put in place, how to report adverse reactions.
Instruktion til injektion af Herceptin ved brug af injektionssystemet
Instructions for injecting Herceptin using the administration system
Instruktion til patienter/omsorgspersoner:
Instructions for use for patients/ carers:
INSTRUKTION TIL SUNDHEDSPERSONALE
INSTRUCTIONS FOR HEALTH CARE PROFESSIONALS
Instruktion til sundhedspersonalet om at læse materialet sammen med produktresuméet.
Instruction for healthcare professionals to read the materials in conjunction with the SmPC.
Instruktion vedrørende bortskaffelse af gasflaske
Instruction for disposal of gas cylinder
Instruktion vedrørende opblanding af den orale suspension
Instructions to reconstitute the oral suspension
Instruktion vedrørende åbning og lukning af æsken
Instruction for opening and closing the box:
Instruktioner for administration
Instructions for administration
Instruktioner for anvendelsen
Instructions for use
Instruktioner for dosisafbrydelse og dosisreduktion af pomalidomid relateret til hæmatologiske bivirkninger er angivet i nedenstående tabel:
Instructions for dose interruptions and reductions for pomalidomide related to haematologic adverse reactions are outlined in the table below:
Instruktioner for dosisjustering af dexamethason
Dexamethasone dose modification instructions
Instruktioner for dosisjustering af pomalidomid
Pomalidomide dose modification instructions
Instruktioner for forberedelse til intravenøs administration for cervixcancer
Instructions for Preparation for Intravenous Administration for Cervical Cancer
Instruktioner for forberedelse til intravenøs administration for småcellet lungecancer
Instructions for Preparation for Intravenous Administration for Small Cell Lung Cancer
Instruktioner for fortynding
Instructions for dilution
INSTRUKTIONER FOR FREMSTILLING AF RADIOAKTIVE LÆGEMIDLER
INSTRUCTION FOR PREPARATION OF RADIOPHARMACEUTICALS
INSTRUKTIONER FOR KLARGØRING AF RADIOAKTIVE LÆGEMIDLER
INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS
Instruktioner for korrekt anvendelse
Instructions for proper use
Instruktioner for rekonstituering:
Instructions for reconstitution:
Instruktioner i anvendelse og håndtering - rekonstitution, fortynding og administration
Instructions for use and handling – reconstitution, dilution and administration
Instruktioner i anvendelse og håndtering rekonstitution, fortynding og administration
Instructions for use and handling – reconstitution, dilution and administration
Instruktioner i brug af NovoRapid PumpCart fyldt cylinderampul
Instructions on how to use NovoRapid PumpCart pre-filled cartridge.
Instruktioner i brug og håndtering – rekonstitution, fortynding og administration
Instructions for use and handling – reconstitution, dilution and administration
Instruktioner i selv at injicere Nordimet
Instructions on injecting yourself with Nordimet
Instruktioner om at forsyne patienter og sundhedsprofessionelle med huskekort til patienter
Instructions to provide patients and caregivers with the patient reminder card